Test Name
Bladder Cancer Panel +3,+7,+17,9p21-
Test Code
F URO
Synonyms
+3,+7,+17, del(9)(p21)
Associations
Bladder Cancer
CPT Codes
88120
Turnaround Time
5
Specimen Requirements
Voided urine must be > 33 mL. Mix voided urine with preservative at 2:1 ratio of urine to preservative (PreservCyt® or Carbowax® solutions) for a total volume > 50 mL.
Specimen Stability
2°C to 8°C, specimens are stable up to 72 hours
Storage & Handling
2°C to 8°C during transit, but specimens may be transported on refrigerated gel packs. Do not allow the gel pack to come in contact with the specimen. Do not freeze. Extreme temperatures should be avoided.
Causes for Rejections
Any non-urine specimen including bladder or renal pelvic washings; Incorrect preservative; Sample exposed to extreme temperature; Insufficient volume or number of cells for analysis; Specimen transport greater than 48 hours
Description
+3,+7,+17, del(9)(p21) is recommended for the evaluation of patients with hematuria who are suspected of having bladder cancer and for monitoring patients for tumor recurrence. An important advantage in the evaluation of bladder cancer patients is that th
References
- Phillips and Richardson. (2006). Aneuploidy in bladder cancers: the utility of fluorescent in situ hybridization in clinical practice. BJU Inter.98:33-37.
- Sarosdy et al. (2006). Use of a multi-target fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria. 176:44-47.
- Skacel et al. (2003). Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol. 169:2101.
